SCHEMBL4078154

SCHEMBL4078154

CC(C)(CO)Nc1nc(-c2ccc(Br)cc2)ns1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 7/20 0.48
MAPT P10636 7/20 0.48
LMNA P02545 6/20 0.48
RXFP1 Q9HBX9 5/20 0.47
THRB P10828 2/20 0.45
SMN1; SMN2 Q16637 5/20 0.43
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
POLB P06746 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
HTT P42858 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ADORA3 P0DMS8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9688868 0.76 LMNA (0.54) TP53MAPTLMNARXFP1THRB
SCHEMBL4077729 0.75 MAPT (0.59) MAPTLMNATHRBSMN1; SMN2NPC1
Bromide SCHEMBL3970513 0.73 MAOA (0.42) MAPTRAB9APOLBMEN1KMT2A
SCHEMBL28952954 0.69 SMN1; SMN2 (0.75) TP53MAPTLMNARXFP1THRB
SCHEMBL30259556 0.66 MAPT (0.44) TP53MAPTLMNARXFP1THRB
SCHEMBL32679828 0.65 CYP19A1 (0.66) TP53MAPTLMNATHRBSMN1; SMN2
SCHEMBL3979477 0.63 LMNA (0.43) TP53MAPTLMNARXFP1THRB
SCHEMBL8804007 0.63 LMNA (0.43) TP53MAPTLMNARXFP1THRB
SCHEMBL4078682 0.63 MEN1 (0.52) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL28861549 0.63 LMNA (0.40) TP53MAPTLMNARXFP1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618990-B2 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy WYETH (US) 2009-11-17 US disclosed
EP-2054410-A2 OXAZOLIDONE DERIVATIVES AS PR MODULATORS Wyeth (US) 2009-05-06 EP disclosed
US-20080045556-A1 Oxazolidone derivatives as PR modulators WYETH (US) 2008-02-21 US disclosed
WO-2008021331-A2 OXAZOLIDONE DERIVATIVES AS PR MODULATORS WYETH (US) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045556-A1 Oxazolidone derivatives as PR modulators MC2R, NPY1R, PRLHR TP53 762/4885MAPT 1550/4885LMNA 2309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.